-
Mashup Score: 0Elranatamab treatment in a multiple myeloma patient undergoing renal dialysis | Published in Clinical Hematology International - 5 hour(s) ago
By Zoé Van de Wyngaert, Irene Romera-Martinez & 6 more. Despite end-stage renal impairment, treatment with the anti-B cell maturation antigen (BCMA)xCD3 bispecific antibody proved feasible without unexpected side effects. Increased attention to infectious risk is crucial for fragile patients.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
By Nausheen Ahmed, Olalekan Oluwole & 3 more. We recommend re-immunizing patients post CAR-T based on CDC and transplant guidelines.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15
By Nausheen Ahmed, Olalekan Oluwole & 3 more. We recommend re-immunizing patients post CAR-T based on CDC and transplant guidelines.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 49
By Jana Sawyer, Taylor Elliott & 4 more. The acute toxicities that occur from conditioning chemotherapy can impact the peri-transplant period and have substantial implications on patients’ tolerability and outcomes, irrespective of the treatment of their disease.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29
By Allison C. Y. Tso, Sanchalika Acharyya & 6 more. Real-world data on the outcome of Asian patients with secondary hemophagocytic lymphohistiocytosis (HLH), especially on dengue-associated HLH, are limited to small case series.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Risks and benefits of cannabis as a pain control modality in patients with sickle cell disease | Published in Clinical Hematology International - 22 day(s) ago
By Jeremy W. Jacobs, Brian D. Adkins & 3 more. Opioids have historically been, and continue to be, the mainstay for managing pain in patients with SCD.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 60
By M Shahzad Rauf, Irfan Maghfoor & 6 more. Our study suggests that in patients with primary refractory DLBCL without initial progressive disease after frontline R-CHOP, the depth of response to SC before HDC–ASCT is predictive of relapse.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 88Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations | Published in Clinical Hematology International - 29 day(s) ago
By Katie Gatwood, Zahra Mahmoudjafari & 6 more. This review provides a summary of currently published experiences, as well as expert opinion regarding implementation of an outpatient CAR-T program.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 38Transfusion Support in Hematopoietic Stem Cell Transplantation: A Contemporary Narrative Review | Published in Clinical Hematology International - 1 month(s) ago
By Brian D. Adkins, Jeremy W. Jacobs & 3 more. Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 81Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations | Published in Clinical Hematology International - 1 month(s) ago
By Katie Gatwood, Zahra Mahmoudjafari & 6 more. This review provides a summary of currently published experiences, as well as expert opinion regarding implementation of an outpatient CAR-T program.
Source: chi.scholasticahq.comCategories: General Medicine News, Hem/OncsTweet
Elranatamab treatment in a myeloma patient undergoing renal dialysis- Published in Clin Hematol Int the official journal of @TheIACH @IMFmyeloma @MyelomaTeacher @MyelomaUK @Florent_Malard @af3m_myelome https://t.co/EKa1l0Mxsz